Aerovate Therapeutics, Inc.
AVTE
$2.68
-$0.04-1.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.80% | -20.65% | -37.07% | -43.88% | -46.61% |
| Total Depreciation and Amortization | 193.75% | 243.18% | 31.33% | 32.05% | 41.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.31% | 36.30% | 75.83% | 102.39% | 93.80% |
| Change in Net Operating Assets | -213.99% | -120.08% | -70.64% | -64.22% | 26.34% |
| Cash from Operations | -25.39% | -31.85% | -46.25% | -53.79% | -45.13% |
| Capital Expenditure | -- | 21.95% | -15.66% | 31.15% | 27.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 366.21% | 133.76% | -49.58% | -87.27% | 68.77% |
| Cash from Investing | 371.78% | 134.37% | -49.72% | -87.51% | 71.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -44.33% | -44.69% | -44.62% | 4,618.28% | 5,927.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.20% | 34.68% | 27.92% | -25.88% | 36.93% |
| Cash from Financing | -44.72% | -44.79% | -44.81% | 7,370.76% | 11,515.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 837.84% | -110.91% | -189.20% | -1,014.24% | 103.44% |